Dale Sander Sells 45,887 Shares of Humacyte (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) CFO Dale Sander sold 45,887 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the chief financial officer directly owned 267,213 shares in the company, valued at $240,491.70. This trade represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.02 on Friday. The company’s 50-day moving average is $0.83 and its 200 day moving average is $1.04. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93. The company has a market capitalization of $226.46 million, a P/E ratio of -1.79 and a beta of 2.31. Humacyte, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $2.93.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, equities research analysts forecast that Humacyte, Inc. will post -0.32 earnings per share for the current year.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. bought a new stake in shares of Humacyte during the second quarter valued at about $28,000. Financial Advisors Network Inc. bought a new stake in shares of Humacyte during the second quarter valued at about $28,000. Truist Financial Corp bought a new stake in shares of Humacyte during the third quarter valued at about $28,000. Cerity Partners LLC bought a new stake in shares of Humacyte during the second quarter valued at about $35,000. Finally, Equitable Holdings Inc. bought a new stake in shares of Humacyte during the third quarter valued at about $29,000. 44.71% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HUMA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. BTIG Research dropped their price objective on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Finally, Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.